Cascadian Therapeutics (ONTY) Inactive 10-Q2017 Q1 Quarterly report

Content analysis

Filed: 9 May 17, 12:00am

May 9, 2017

/s/ Scott D. Myers

Scott D. Myers

President and Chief Executive Officer

(Principal Executive Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abroad, add, Adimab, Antonio, assessing, Assessment, Australia, blocking, category, circumvent, circumvented, codified, Congressional, copy, correspondingly, defense, dispute, duration, easier, endpoint, Enterprise, epidermal, exempt, exemption, expedite, expertise, factor, factual, feasibility, filer, fill, forfeiture, fraction, GMP, goodwill, half, halt, important, Israel, licensor, locally, long, misappropriating, Mitigation, NDA, NEA, pace, PFS, pharmacology, pivotal, placebo, play, prospectively, radiologic, reinstated, repeal, resigned, Restoration, retroactively, sample, San, satisfy, secondary, serve, settled, Similarly, Simplifying, slower, space, Steering, Step, strong, submission, subset, suitable, Symposium, taxane, thought, TIGIT, TKI, trademark, triplet, unexpected, unmet, valuable, withholding, world, worldwide, wrongfully

Removed: accounted, activated, advance, afforded, alleged, asset, assigned, ASU, behalf, breadth, Brian, California, Cambridge, capable, cGMP, challenge, classifying, clear, competitor, Concurrently, consecutive, consolidation, consultant, defendant, delisting, detail, District, DNA, doxorubicin, Dr, efficient, Eli, employment, enforce, evaluate, exchanged, expiration, exploited, facilitating, financed, Form, function, Fyfe, Genentech, generated, GlaxoSmithKline, grace, Gwen, high, inherently, insider, INSPIRE, integrate, intense, invalid, invention, inventorship, KGaA, Kingdom, leadership, Lessor, letter, Lilly, liposomal, listing, low, lymphoma, marked, measurement, Merck, Merrimack, method, negotiation, nominal, nominated, Northern, NSCLC, occurrence, October, Oncothyreon, opposed, originated, outlined, parallel, patentable, path, practice, preserve, president, producing, profitably, protein, Puma, rebuild, recover, refractory, regain, regulate, relationship, reliant, relief, remove, replicable, replication, represent, reversed, Sand, Scott, solid, stay, Stimuvax, sublicensing, Subtopic, tecemotide, transition, Trust, tumor, unauthorized, underlying, underwriter, vaccine, weak, wrongdoing, Zachary

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ONTY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

I, Scott D. Myers, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report onForm 10-Q of Cascadian Therapeutics, Inc. for the quarterly period ended March 31, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report onForm 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cascadian Therapeutics, Inc.